Methods for alleviating symptoms of premenstrual syndrome and late luteal phase dysphoric disorder

• US 5,733,937 A
• Filed: 02/21/1997
• Issued: 03/31/1998
• Est. Priority Date: 02/28/1996
• Status: Expired due to Fees

• Current Assignee: Pfizer Inc.
• Original Assignee: Pfizer Inc.
• Inventors: Thompson, David D., MacLean, David B.
• Primary Examiner(s): Goldberg, Jerome D.
• Application Number:
  US08/804,702
• Time in Patent Office: 403 Days
• Field of Search: 514/648
• US Class Current: 514/648
• CPC Class Codes: A61K 31/138 Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377

Abstract

The present invention provides novel methods of inhibiting the symptoms of premenstrual syndrome comprising administering to a human in need of treatment an effective amount of a compound of formula I ##STR1## wherein R¹ and R² may be the same or different provided that, when R¹ and R² are the same, each is a methyl or ethyl group, and, when R¹ and R² are different, one of them is a methyl or ethyl group and the other is hydrogen or a benzyl group; or a pharmaceutically acceptable salt thereof.

Claims

1. A method for inhibiting the symptoms of premenstrual syndrome comprising administering to a human in need of treatment an effective amount of a compound of formula I ##STR4## wherein R¹ and R² may be the same or different provided that, when R¹ and R² are the same, each is a methyl or ethyl group, and, when R¹ and R² are different, one of them is a methyl or ethyl group and the other is hydrogen or a benzyl group;

or a pharmaceutically acceptable salt thereof.

2. A method according to claim 1 wherein the compound of formula I is a compound wherein R¹ and R² each are methyl, or a pharmaceutically acceptable salt thereof.

3. A method according to claim 2 wherein said salt thereof is the citrate salt.